Real‐world treatment outcomes of immune checkpoint inhibitors used off‐label in oncology: A comprehensive cancer institution experience

Real‐world treatment outcomes of immune checkpoint inhibitors used off‐label in oncology: A comprehensive cancer institution experience

Abstract Off‐label use (OLU) is quite common in oncology due to the complexity of cancer and the time‐consuming regulatory process. However, outcomes of OLU in cancer treatment remain unclear. This study aimed to evaluate the overall survival (OS), event‐free survival (EFS), duration of treatment (D...

Full description

Bibliographic Details
Main Authors: Sandra Fontanals, Anna Esteve, Andrea González, Cristina Ibáñez, Ricard Mesía, Ana Clopés
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Pharmacology Research & Perspectives
Subjects:
cancer
immune checkpoint inhibitors
off‐label use
survival
treatment outcomes
Online Access:https://doi.org/10.1002/prp2.1167

Internet

https://doi.org/10.1002/prp2.1167

Similar Items